7-Bromo-1H-indazole-3-carboxylic acid, 95.0%, 250mg

(R)-3-(tert-Butoxy)-2-((tert-butoxycarbonyl)amino)propanoic acid, 95.0%, 50g

(+)-2,2'-Methylenebis[(3aR,8aS)-3a,8a-dihydro-8H-indeno[1,2-d]oxazole]>98.0%(HPLC)(N)100mg

(S)-N-(Piperidin-3-yl)pyridine-2-carboxamide dihydrochloride, 1g

Potassium trimethylsilanolate, 2M in THF (26-29wgt%), 95%, 100g

(S)-4-(6-(3,5-Dimethylisoxazol-4-yl)-1-(1-(pyridin-2-yl)ethyl)-1H-pyrrolo[3,2-b]pyridin-3-yl)benzoic acid, 98.00%, 5mg

2-Bromo-6-methoxynicotinic acid, 95%, 250mg

2-(4-Methoxyphenyl)malondialdehyde, 95.0%, 1g

2-Methyl-2-phenylpropan-1-amine, 97.0%, 5g

1',3'-Dihydrospiro[imidazolidine-4,2'-indene]-2,5-dione, 95.0%, 5g

2-Chloro-4,5-difluoro-benzonitrile, 97.0%, 1g

1-(2,4-Dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl)ethan-1-ol, 97%, 5g

4-(TERT-BUTYL)-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-[2,2'-BIPYRIMIDIN]-4-YL)BENZENESULFONAMIDE, 95%, 250mg